Sort
23,748 grants matching “melanoma”
High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy
$684,659Udai S Kammula · Basic Sciences · Z01 · FY2007 · CA
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis
$684,278Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
The Epigenetic Enzyme CARM1 as a Negative Regulator of Dendritic cells and CD8 T cells in Melanoma
$683,670Kai W Wucherpfennig · Massachusetts General Hospital · P01 · FY2025 · CA
An INteractive Survivorship Program to Improve Healthcare REsources [INSPIRE] for Adolescent and Young Adult (AYA) Cancer Survivors
$683,516Kevin S Baker · Fred Hutchinson Cancer Center · U01 · FY2024 · CA
Imaging Acidosis and Immune Therapy in PDAC
$683,503Robert J Gillies · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
Imaging Acidosis and Immune Therapy in PDAC
$683,503Shari Pilon-Thomas · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Structural and functional characterization of T and NK cell receptors
$683,452Peter D. Sun · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia
$683,443Robert K Bradley · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy
$683,382Udai S Kammula · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
CHARACTERIZATION OF NEUROPILIN, A NOVEL VEGF RECEPTOR
$683,003Michael Klagsbrun · Boston Children'S Hospital · R37 · FY2008 · CA
Immunogenetic determinants of cancer risk
$682,727Robert M Samstein · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
$682,689David A. Hafler · Yale University · R01 · FY2025 · CA
Using Technology to Scale-Up an Occupational Sun Protection Policy Program
$682,639David B Buller · Klein Buendel, Inc. · R01 · FY2017 · CA
Endothelial Toll-like Receptor 3 in the pathogenesis and therapy of Pulmonary Arterial Hypertension
$682,581Laszlo Farkas · Virginia Commonwealth University · R01 · FY2019 · HL
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy
$682,539Daniel B Stetson · University Of Washington · R01 · FY2023 · CA
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation
$682,315Katerina Abigail Politi · Yale University · R01 · FY2021 · CA
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
$682,247Meghan E. Sise · Massachusetts General Hospital · R01 · FY2024 · DK
Transcriptional mechanisms and melanoma
$682,142Leonard I Zon · Massachusetts General Hospital · P01 · FY2025 · CA
Nano-scale proteomic analysis: development, implementation, and applications
$681,836Jinqiu Chen · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA
A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women
$681,600David J. Margolis · University Of Pennsylvania · U01 · FY2025 · AR
ELUCIDATING CLONAL COMPETITION THROUGH FLUORESCENT COLOR CODING OF MELANOMA CELLS
$681,572The General Hospital Corporation · · FY2017 · Department of the Army
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy
$681,404Daniel B Stetson · University Of Washington · R01 · FY2024 · CA
Intra-operative confocal imaging to guide Mohs surgery
$681,221Milind Rajadhyaksha · Sloan-Kettering Inst Can Research · R01 · FY2010 · EB
Metabolic regulation of immunosuppressive myeloid cells in the tumor microenvironment of pancreatic cancer.
$681,198Yaqing Zhang · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
MATCHMAKERS - Creating and training AI tools for TCR binding prediction and design
$681,176Michael Birnbaum · Massachusetts Institute Of Technology · OT2 · FY2024 · CA